The Russian Ministry of Health has issued a registration certificate to the Russian pharmaceutical company Geropharm for the drug RinLis® (insulin lispro), which is an ultra-fast insulin based on the active substance insulin lispro. This development is a bioanalogue of the drug Lyumjev of Eli Lilly, which never appeared on the Russian market.
According to the press service of Geropharm, large-scale clinical trials conducted in leading Russian scientific centers confirmed the identity of the safety and efficacy profiles of the new and reference drugs. One of the key advantages of the new ultra-fast insulin is the ability to administer it immediately before or within 20 minutes after a meal.
